Skip to main content
Top

Open Access 09-04-2024 | Psoriatic Arthritis | Original Research

Clinical Characteristics of “Severe” Peripheral Psoriatic Arthritis: A Retrospective Analysis of a Longitudinal Cohort

Authors: Ennio Lubrano, Silvia Scriffignano, Fabio Massimo Perrotta

Published in: Rheumatology and Therapy

Login to get access

Abstract

Introduction

The concept of severity in a multidomain disease such as psoriatic arthritis (PsA) is still not well defined. The aim of this study was to identify the clinical characteristics of patients with severe peripheral PsA.

Methods

Retrospective analysis of a longitudinal cohort. Demographic and clinical characteristics of patients with PsA were collected at baseline and at last follow-up. We defined the severe population using the modified Composite Psoriatic Disease Activity Index (mCPDAI); which excludes ankylosing spondylitis quality of life scale). Hence, patients with a score of 3 in at least one domain were defined as having severe PsA. Clinical characteristics of patients fulfilling the definition of severe PsA were compared to those non-severe.

Results

We evaluated 177 patients with peripheral PsA (M/F: 98/76). Of these, 64 (36.1%) were identified as severe according to the mCPDAI criteria, at baseline. Eighteen patients (10.1%) at last follow-up still met the definition of severe PsA. At last follow-up visit, severe patients with PsA were only males (18/18, P < 0.01) and have worse outcomes in terms of disease activity, pain, function, and impact of disease. Male sex and the severity of skin involvement at baseline were factors associated with the presence of severe PsA. The agreement between the presence of severe PsA and the absence of minimal disease activity was slight [Cohen’s k: 0.174 (0.084–0.264)].

Conclusions

Our study showed that severe patients with PsA had more disease activity, pain, and impact of disease than non-severe patients. Furthermore, we demonstrated that severity and disease activity are not interchangeable concepts.
Literature
1.
go back to reference Lubrano E, Scriffignano S, Perrotta FM. Psoriatic arthritis, psoriatic disease, or psoriatic syndrome? J Rheumatol. 2019;46:1428–30.CrossRefPubMed Lubrano E, Scriffignano S, Perrotta FM. Psoriatic arthritis, psoriatic disease, or psoriatic syndrome? J Rheumatol. 2019;46:1428–30.CrossRefPubMed
3.
go back to reference Coates LC, Lubrano E, Perrotta FM, Emery P, Conaghan PG, Helliwell PS. What should be the primary target of “Treat to Target” in psoriatic arthritis? J Rheumatol. 2019;46:38–42.CrossRefPubMed Coates LC, Lubrano E, Perrotta FM, Emery P, Conaghan PG, Helliwell PS. What should be the primary target of “Treat to Target” in psoriatic arthritis? J Rheumatol. 2019;46:38–42.CrossRefPubMed
4.
go back to reference Lubrano E, Scriffignano S, Perrotta FM. Residual disease activity and associated factors in psoriatic arthritis. J Rheumatol. 2020;47:1490–5.CrossRefPubMed Lubrano E, Scriffignano S, Perrotta FM. Residual disease activity and associated factors in psoriatic arthritis. J Rheumatol. 2020;47:1490–5.CrossRefPubMed
5.
go back to reference Coates LC, de Wit M, Buchanan-Hughes A, Smulders M, Sheahan A, Ogdie AR. Residual disease associated with suboptimal treatment response in patients with psoriatic arthritis: a systematic review of real-world evidence. Rheumatol Ther. 2022;9:803–21.CrossRefPubMedPubMedCentral Coates LC, de Wit M, Buchanan-Hughes A, Smulders M, Sheahan A, Ogdie AR. Residual disease associated with suboptimal treatment response in patients with psoriatic arthritis: a systematic review of real-world evidence. Rheumatol Ther. 2022;9:803–21.CrossRefPubMedPubMedCentral
6.
go back to reference Hagège B, Tan E, Gayraud M, Fautrel B, Gossec L, Mitrovic S. Remission and low disease activity in psoriatic arthritis publications: a systematic literature review with meta-analysis. Rheumatology (Oxford). 2020;59:1818–25.CrossRefPubMed Hagège B, Tan E, Gayraud M, Fautrel B, Gossec L, Mitrovic S. Remission and low disease activity in psoriatic arthritis publications: a systematic literature review with meta-analysis. Rheumatology (Oxford). 2020;59:1818–25.CrossRefPubMed
7.
go back to reference Perrotta FM, Marchesoni A, Lubrano E. Minimal disease activity and remission in psoriatic arthritis patients treated with anti-TNF-α drugs. J Rheumatol. 2016;43:350–5.CrossRefPubMed Perrotta FM, Marchesoni A, Lubrano E. Minimal disease activity and remission in psoriatic arthritis patients treated with anti-TNF-α drugs. J Rheumatol. 2016;43:350–5.CrossRefPubMed
8.
go back to reference Coates LC, Fransen J, Helliwel PS. Defining disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis. 2010;69:48–53.CrossRefPubMed Coates LC, Fransen J, Helliwel PS. Defining disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis. 2010;69:48–53.CrossRefPubMed
9.
go back to reference Eder L, Gladman DD. Predictors for clinical outcome in psoriatic arthritis—what have we learned from cohort studies? Expert Rev Clin Immunol. 2014;10:763–70.CrossRefPubMed Eder L, Gladman DD. Predictors for clinical outcome in psoriatic arthritis—what have we learned from cohort studies? Expert Rev Clin Immunol. 2014;10:763–70.CrossRefPubMed
10.
go back to reference Theander E, Husmark T, Alenius GM, et al. Early psoriatic arthritis: short symptom duration, male gender and preserved physical functioning at presentation predict favourable outcome at 5-year follow-up. Results from the Swedish Early Psoriatic Arthritis Register (SwePsA). Ann Rheum Dis. 2014;73:407–13.CrossRefPubMed Theander E, Husmark T, Alenius GM, et al. Early psoriatic arthritis: short symptom duration, male gender and preserved physical functioning at presentation predict favourable outcome at 5-year follow-up. Results from the Swedish Early Psoriatic Arthritis Register (SwePsA). Ann Rheum Dis. 2014;73:407–13.CrossRefPubMed
11.
go back to reference Lubrano E, Scriffignano S, de Vlam K, Ronga M, Perrotta FM, Lories R. Triple jump for the optimal management of psoriatic arthritis: diet, sleep and exercise—a review. RMD Open. 2023;9: e003339.CrossRefPubMedPubMedCentral Lubrano E, Scriffignano S, de Vlam K, Ronga M, Perrotta FM, Lories R. Triple jump for the optimal management of psoriatic arthritis: diet, sleep and exercise—a review. RMD Open. 2023;9: e003339.CrossRefPubMedPubMedCentral
12.
go back to reference Queiro R, Seoane-Mato D, Laiz A, et al. Severe disease in patients with recent-onset psoriatic arthritis. Prediction model based on machine learning. Front Med (Lausanne). 2022;9:891863.CrossRefPubMedPubMedCentral Queiro R, Seoane-Mato D, Laiz A, et al. Severe disease in patients with recent-onset psoriatic arthritis. Prediction model based on machine learning. Front Med (Lausanne). 2022;9:891863.CrossRefPubMedPubMedCentral
16.
go back to reference Mumtaz A, Gallagher P, Kirby B, et al. Development of a preliminary composite disease activity index in psoriatic arthritis. Ann Rheum Dis. 2011;70:272–7.CrossRefPubMed Mumtaz A, Gallagher P, Kirby B, et al. Development of a preliminary composite disease activity index in psoriatic arthritis. Ann Rheum Dis. 2011;70:272–7.CrossRefPubMed
17.
go back to reference Helliwell PS, FitzGerald O, Fransen J. Composite disease activity and responder indices for psoriatic arthritis: a report from the GRAPPA 2013 meeting on development of cutoffs for both disease activity states and response. J Rheumatol. 2014;41:1212–7.CrossRefPubMed Helliwell PS, FitzGerald O, Fransen J. Composite disease activity and responder indices for psoriatic arthritis: a report from the GRAPPA 2013 meeting on development of cutoffs for both disease activity states and response. J Rheumatol. 2014;41:1212–7.CrossRefPubMed
18.
go back to reference Taylor W, Gladman D, Helliwell P, et al. CASPAR Study Group. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54:2665–73.CrossRefPubMed Taylor W, Gladman D, Helliwell P, et al. CASPAR Study Group. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54:2665–73.CrossRefPubMed
21.
go back to reference Healy PJ, Helliwell PS. Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific to psoriatic arthritis. Arthritis Rheum. 2008;59(5):686–91.CrossRefPubMed Healy PJ, Helliwell PS. Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific to psoriatic arthritis. Arthritis Rheum. 2008;59(5):686–91.CrossRefPubMed
22.
go back to reference Schoels MM, Aletaha D, Alasti F, et al. Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score. Ann Rheum Dis. 2016;75:811–8.CrossRefPubMed Schoels MM, Aletaha D, Alasti F, et al. Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score. Ann Rheum Dis. 2016;75:811–8.CrossRefPubMed
23.
go back to reference Lubrano E, Scriffignano S, Azuaga AB, Ramirez J, Cañete JD, Perrotta FM. Assessment of the Patient Acceptable Symptom State (PASS) in psoriatic arthritis: association with disease activity and quality of life indices. RMD Open. 2020;6: e001170.CrossRefPubMedPubMedCentral Lubrano E, Scriffignano S, Azuaga AB, Ramirez J, Cañete JD, Perrotta FM. Assessment of the Patient Acceptable Symptom State (PASS) in psoriatic arthritis: association with disease activity and quality of life indices. RMD Open. 2020;6: e001170.CrossRefPubMedPubMedCentral
24.
go back to reference Gossec L, de Wit M, Kiltz U, et al. EULAR PsAID Taskforce. A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative. Ann Rheum Dis. 2014;73:1012–9.CrossRefPubMed Gossec L, de Wit M, Kiltz U, et al. EULAR PsAID Taskforce. A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative. Ann Rheum Dis. 2014;73:1012–9.CrossRefPubMed
26.
go back to reference Lubrano E, Perrotta FM. Sex-related differences in psoriatic arthritis. Lancet Rheumatol. 2023;5:699–701.CrossRef Lubrano E, Perrotta FM. Sex-related differences in psoriatic arthritis. Lancet Rheumatol. 2023;5:699–701.CrossRef
Metadata
Title
Clinical Characteristics of “Severe” Peripheral Psoriatic Arthritis: A Retrospective Analysis of a Longitudinal Cohort
Authors
Ennio Lubrano
Silvia Scriffignano
Fabio Massimo Perrotta
Publication date
09-04-2024
Publisher
Springer Healthcare
Published in
Rheumatology and Therapy
Print ISSN: 2198-6576
Electronic ISSN: 2198-6584
DOI
https://doi.org/10.1007/s40744-024-00667-0
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.